|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Collaboration revenue | |||||
| Operating expenses: | |||||
| Research and development | |||||
| General and administrative | |||||
| Impairment loss | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| Other income: | |||||
| Interest income | |||||
| Change in fair value of stock price appreciation milestones | |||||
| Other income | |||||
| Total other income | |||||
| Net loss | |||||
| Other comprehensive gain: | |||||
| Unrealized gain (loss) on available-for-sale securities, net | |||||
| Comprehensive loss | |||||
| Net loss per share, Basic | |||||
| Net loss per share, Diluted | |||||
| Weighted-average common shares used to compute basic net loss per share | |||||
| Weighted-average common shares used to compute diluted net loss per share | |||||
Loading...